{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,21]],"date-time":"2026-08-21T12:40:12Z","timestamp":1787316012803,"version":"build-2736575974"},"reference-count":43,"publisher":"MDPI AG","issue":"3","license":[{"start":{"date-parts":[[2024,2,3]],"date-time":"2024-02-03T00:00:00Z","timestamp":1706918400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004334","name":"Merck Sharp &amp; Dohme","doi-asserted-by":"publisher","award":["P2135"],"award-info":[{"award-number":["P2135"]}],"id":[{"id":"10.13039\/100004334","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JCM"],"abstract":"<jats:p>Background: This phase II study evaluated the efficacy and safety of the histone deacetylase (HDAC) inhibitor, vorinostat, administered in combination with paclitaxel and carboplatin in patients with platinum sensitive recurrent ovarian cancer. Methods: Women with recurrent platinum-sensitive ovarian, peritoneal, or Fallopian tube carcinoma, a performance status of 0\u20132, and good overall organ function were eligible. Patients received 6 courses of paclitaxel (175 mg\/m2) and carboplatin area under the curve (AUC) of 5.0 mg\/mL\/min administered via intravenous infusion on day 1 of a 3-week schedule. In addition, patients received vorinostat 400 mg orally once daily on days \u22124 through 10 of Cycle 1 and days 1 through 14 of each subsequent treatment cycle. The primary endpoints were progression-free survival (PFS) and adverse events. The secondary endpoints were the objective response rate and overall survival. Results: Fifty-five patients were included. CR was obtained in 14 patients (26.4%) and PR in 19 patients (35.8%), resulting in an ORR of 62.2%. Twenty patients (37.7%) had SD. The median duration of response (DoR) was 12.6 (range 6\u2013128) months. The median PFS was 11.6 months (95% CI, 10.3\u201318.0; p &lt; 0.001). Median OS was 40.6 months (95% Cl, 25.1\u201356.1). The most common treatment-related adverse events (all grades) were fatigue, anemia, thrombocytopenia, neutropenia, anorexia, nausea, pain, sensory neuropathy, myalgia, stomatitis and diarrhea. Conclusions: Vorinostat combined with carboplatin plus paclitaxel was tolerable and generated significant responses including a long median overall survival in recurrent platinum-sensitive ovarian cancer.<\/jats:p>","DOI":"10.3390\/jcm13030897","type":"journal-article","created":{"date-parts":[[2024,2,6]],"date-time":"2024-02-06T12:38:24Z","timestamp":1707223104000},"page":"897","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":13,"title":["Carboplatin plus Paclitaxel in Combination with the Histone Deacetylate Inhibitor, Vorinostat, in Patients with Recurrent Platinum-Sensitive Ovarian Cancer"],"prefix":"10.3390","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4557-2251","authenticated-orcid":false,"given":"Hanieh","family":"Meteran","sequence":"first","affiliation":[{"name":"Department of Clinical Oncology and Palliative Care, Zealand University Hospital, 4000 Roskilde, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0002-1871-3087","authenticated-orcid":false,"given":"Anja \u00d8r","family":"Knudsen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Odense University Hospital, 5000 Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Trine Lembrecht","family":"J\u00f8rgensen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Odense University Hospital, 5000 Odense, Denmark"},{"name":"Institute of Clinical Research, University of Southern Denmark, 5230 Odense, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorte","family":"Nielsen","sequence":"additional","affiliation":[{"name":"Department of Oncology, Copenhagen University Hospital, Herlev and Gentofte Hospital, 2730 Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8844-6546","authenticated-orcid":false,"given":"J\u00f8rn","family":"Herrstedt","sequence":"additional","affiliation":[{"name":"Department of Clinical Oncology and Palliative Care, Zealand University Hospital, 4000 Roskilde, Denmark"},{"name":"Department of Oncology, Odense University Hospital, 5000 Odense, Denmark"},{"name":"Department of Oncology, Copenhagen University Hospital, Herlev and Gentofte Hospital, 2730 Copenhagen, Denmark"},{"name":"Department of Clinical Medicine, Faculty of Health and Medical Sciences, University of Copenhagen, 2200 Copenhagen, Denmark"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2024,2,3]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"7","DOI":"10.3322\/caac.21654","article-title":"Cancer statistics","volume":"71","author":"Siegel","year":"2021","journal-title":"CA Cancer J. Clin."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1074\/mcp.R400006-MCP200","article-title":"Progress and challenges in screening for early detection of ovarian cancer","volume":"3","author":"Jacobs","year":"2004","journal-title":"Mol. Cell. Proteom."},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"284","DOI":"10.3322\/caac.21456","article-title":"Ovarian cancer statistics, 2018","volume":"68","author":"Torre","year":"2018","journal-title":"CA Cancer J. Clin."},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"The ICON Group (2002). Paclitaxel plus carboplatin versus standard chemotherapy with either single-agent carboplatin or cy-clophosphamide, doxorubicin, and cisplatin in women with ovarian cancer: The ICON3 randomised trial. Lancet, 360, 505\u2013515.","DOI":"10.1016\/S0140-6736(02)09738-6"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"3120","DOI":"10.1200\/JCO.2004.05.195","article-title":"Duration of response to second-line, platinum-based chemotherapy for ovarian cancer: Implications for patient management and clinical trial design","volume":"22","author":"Markman","year":"2004","journal-title":"J. Clin. Oncol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1016\/S0140-6736(17)33326-3","article-title":"Global surveillance of trends in cancer survival 2000\u201314 (CONCORD-3): Analysis of individual records for 37,513,025 patients diagnosed with one of 18 cancers from 322 population-based registries in 71 countries","volume":"391","author":"Allemani","year":"2018","journal-title":"Lancet"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1136\/ijgc-2019-000308","article-title":"ESMO\u2013ESGO consensus conference recommendations on ovarian cancer: Pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease","volume":"29","author":"Colombo","year":"2019","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1200\/JCO.2005.03.2938","article-title":"Addition of Epirubicin As a Third Drug to Carboplatin-Paclitaxel in First-Line Treatment of Advanced Ovarian Cancer: A Prospectively Randomized Gynecologic Cancer Intergroup Trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d\u2019Investigateurs Nationaux pour l\u2019Etude des Cancers Ovariens","volume":"24","author":"Weber","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"4162","DOI":"10.1200\/JCO.2009.27.4696","article-title":"Phase III Trial of carboplatin plus paclitaxel with or without gemcitabine in first-line treatment of epithelial ovarian cancer","volume":"28","author":"Herrstedt","year":"2010","journal-title":"J. Clin. Oncol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1038\/s41392-021-00572-w","article-title":"Small molecules in targeted cancer therapy: Advances, challenges, and future perspectives","volume":"6","author":"Zhong","year":"2021","journal-title":"Signal Transduct. Target. Ther."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2154","DOI":"10.1056\/NEJMoa1611310","article-title":"Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer","volume":"375","author":"Mirza","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1186\/s13048-019-0579-0","article-title":"Maintenance therapy for recurrent epithelial ovarian cancer: Current therapies and future perspectives\u2014A review","volume":"12","author":"Gupta","year":"2019","journal-title":"J. Ovarian Res."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"284","DOI":"10.1038\/nrclinonc.2016.191","article-title":"Delivering widespread BRCA testing and PARP inhibition to patients with ovarian cancer","volume":"14","author":"George","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"ref_14","doi-asserted-by":"crossref","unstructured":"Jenke, R., Re\u00dfing, N., Hansen, F.K., Aigner, A., and B\u00fcch, T. (2021). Anticancer Therapy with HDAC inhibitors: Mechanism-based combination strategies and future perspectives. Cancers, 13.","DOI":"10.3390\/cancers13040634"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1038\/35106079","article-title":"Histone deacetylases and cancer: Causes and therapies","volume":"1","author":"Marks","year":"2001","journal-title":"Nat. Rev. Cancer"},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"e164","DOI":"10.1002\/onco.13551","article-title":"FDA Approval Summary: Olaparib Monotherapy or in Combination with Bevacizumab for the Maintenance Treatment of Patients with Advanced Ovarian Cancer","volume":"26","author":"Arora","year":"2021","journal-title":"Oncologist"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"182","DOI":"10.1016\/j.ygyno.2008.01.009","article-title":"A phase II study of vorinostat in the treatment of persistent or recurrent epithelial ovarian or primary peritoneal carcinoma: A Gynecologic Oncology Group study","volume":"109","author":"Modesitt","year":"2008","journal-title":"Gynecol. Oncol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1016\/j.ejca.2010.02.047","article-title":"Phase II trial of the histone deacetylase inhibitor Belinostat in women with platinum resistant epithelial ovarian cancer and micropapillary (LMP) ovarian tumors","volume":"46","author":"Mackay","year":"2010","journal-title":"Eur. J. Cancer"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.ygyno.2012.02.019","article-title":"A phase II evaluation of belinostat and carboplatin in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube, or primary peritoneal carcinoma: A gynecologic oncology group study","volume":"125","author":"Dizon","year":"2012","journal-title":"Gynecol. Oncol."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1097\/IGC.0b013e31825736fd","article-title":"Phase II activity of belinostat (PXD-101), carboplatin, and paclitaxel in women with previously treated ovarian cancer","volume":"22","author":"Dizon","year":"2012","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_21","first-page":"539","article-title":"Histone Deacetylase Inhibitors Enhance Paclitaxel-induced Cell Death in Ovarian Cancer Cell Lines Independent of p53 Status","volume":"24","author":"Chobanian","year":"2004","journal-title":"Anticancer Res."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Ramarao-Milne, P., Kondrashova, O., Barry, S., Hooper, J.D., Lee, J.S., and Waddell, N. (2021). Histone modifying enzymes in gynaecological cancers. Cancers, 13.","DOI":"10.3390\/cancers13040816"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"201","DOI":"10.3892\/ol.2021.12462","article-title":"HDAC6-selective inhibitors enhance anticancer effects of paclitaxel in ovarian cancer cells","volume":"21","author":"Yoo","year":"2021","journal-title":"Oncol. Lett."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"3605","DOI":"10.1158\/1078-0432.CCR-07-0162","article-title":"Phase I and Pharmacokinetic Study of Vorinostat, A Histone Deacetylase Inhibitor, in Combination with Carboplatin and Paclitaxel for Advanced Solid Malignancies","volume":"13","author":"Ramalingam","year":"2007","journal-title":"Clin. Cancer Res."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"i13","DOI":"10.1093\/annonc\/mdi823","article-title":"ESMO minimum clinical recommendations for diagnosis, treatment and follow-up of epithelial ovarian carcinoma","volume":"16","author":"Vasey","year":"2005","journal-title":"Ann. Oncol."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/IGC.0b013e3182070f17","article-title":"Definitions for Response and Progression in Ovarian Cancer Clinical Trials Incorporating RECIST 1.1 and CA 125 Agreed by the Gynecological Cancer Intergroup (GCIG)","volume":"21","author":"Rustin","year":"2011","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1093\/jnci\/92.3.205","article-title":"New Guidelines to Evaluate the Response to Treatment in Solid Tumors","volume":"92","author":"Therasse","year":"2000","journal-title":"J. Natl. Cancer Inst."},{"key":"ref_28","doi-asserted-by":"crossref","unstructured":"The ICON and AGO Collaborators (2003). Paclitaxel plus platinum-based chemotherapy versus conventional platinum-based chemotherapy in women with relapsed ovarian cancer: The ICON4\/AGO-OVAR-2.2 trial. Lancet, 361, 2099\u20132106.","DOI":"10.1016\/S0140-6736(03)13718-X"},{"key":"ref_29","first-page":"1121","article-title":"Clinical endpoints in oncology\u2014A primer","volume":"11","author":"Delgado","year":"2021","journal-title":"Am. J. Cancer Res."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1038\/bjc.2012.307","article-title":"Final overall survival results of phase III GCIG CALYPSO trial of pegylated liposomal doxorubicin and carboplatin vs. paclitaxel and carboplatin in platinum-sensitive ovarian cancer patients","volume":"107","author":"Wagner","year":"2012","journal-title":"Br. J. Cancer"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"4699","DOI":"10.1200\/JCO.2006.06.0913","article-title":"Gemcitabine plus carboplatin compared with carboplatin in patients with platinum-sensitive recurrent ovarian cancer: An intergroup trial of the AGO-OVAR, the NCIC CTG, and the EORTC GCG","volume":"24","author":"Pfisterer","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1097\/IGC.0b013e31828566f1","article-title":"Increased incidence of severe gastrointestinal events with first-line paclitaxel, carboplatin, and vorinostat chemotherapy for advanced-stage epithelial ovarian, primary peritoneal, and fallopian tube cancer","volume":"23","author":"Mendivil","year":"2013","journal-title":"Int. J. Gynecol. Cancer"},{"key":"ref_33","first-page":"1999","article-title":"Synergistic antitumor effects of histone deacetylase inhibitor scriptaid and bortezomib against ovarian cancer cells","volume":"39","author":"Janyst","year":"2018","journal-title":"Oncol. Rep."},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00280-015-2813-9","article-title":"Phase I study of combination of vorinostat, carboplatin, and gemcitabine in women with recurrent, platinum-sensitive epithelial ovarian, fallopian tube, or peritoneal cancer","volume":"76","author":"Matulonis","year":"2015","journal-title":"Cancer Chemother. Pharmacol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"4968","DOI":"10.1200\/JCO.23.01423","article-title":"Progression-free survival should not be used as a primary end point for registration of anticancer drugs","volume":"41","author":"Booth","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"2039","DOI":"10.1200\/JCO.2012.42.0505","article-title":"OCEANS: A randomized, double-blind, placebo-controlled phase III trial of chemotherapy with or without bevacizumab in patients with platinum-sensitive recurrent epithelial ovarian, primary peritoneal, or fallopian tube cancer","volume":"30","author":"Aghajanian","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1949","DOI":"10.1016\/S0140-6736(17)32440-6","article-title":"Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): A randomised, double-blind, placebo-controlled, phase 3 trial","volume":"390","author":"Coleman","year":"2017","journal-title":"Lancet"},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"2968","DOI":"10.1200\/JCO.18.02238","article-title":"Niraparib Maintenance Therapy in Patients with Recurrent Ovarian Cancer after a Partial Response to the Last Platinum-Based Chemotherapy in the ENGOT-OV16\/NOVA Trial","volume":"37","author":"Matulonis","year":"2019","journal-title":"J. Clin. Oncol."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"620","DOI":"10.1016\/S1470-2045(21)00073-5","article-title":"Olaparib tablets as maintenance therapy in patients with platinum-sensitive relapsed ovarian cancer and a BRCA1\/2 mutation (SOLO2\/ENGOT-Ov21): A final analysis of a double-blind, randomised, placebo-controlled, phase 3 trial","volume":"22","author":"Poveda","year":"2021","journal-title":"Lancet Oncol."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1200\/JCO.22.01549","article-title":"Overall Survival with Maintenance Olaparib at a 7-Year Follow-Up in Patients with Newly Diagnosed Advanced Ovarian Cancer and a BRCA Mutation: The SOLO1\/GOG 3004 Trial","volume":"41","author":"Disilvestro","year":"2023","journal-title":"J. Clin. Oncol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/j.neo.2021.12.002","article-title":"Panobinostat enhances olaparib efficacy by modifying expression of homologous recombination repair and immune transcripts in ovarian cancer","volume":"24","author":"Wilson","year":"2022","journal-title":"Neoplasia"},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"105695","DOI":"10.1016\/j.phrs.2021.105695","article-title":"Histone deacetylase 2 selective inhibitors: A versatile therapeutic strategy as next generation drug target in cancer therapy","volume":"170","author":"Shetty","year":"2021","journal-title":"Pharmacol. Res."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"4695","DOI":"10.18632\/oncotarget.6618","article-title":"The role of HDAC2 in chromatin remodelling and response to chemotherapy in ovarian cancer","volume":"7","author":"Huang","year":"2015","journal-title":"Oncotarget"}],"container-title":["Journal of Clinical Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/3\/897\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T13:54:29Z","timestamp":1760104469000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2077-0383\/13\/3\/897"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,3]]},"references-count":43,"journal-issue":{"issue":"3","published-online":{"date-parts":[[2024,2]]}},"alternative-id":["jcm13030897"],"URL":"https:\/\/doi.org\/10.3390\/jcm13030897","relation":{},"ISSN":["2077-0383"],"issn-type":[{"value":"2077-0383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,3]]}}}